Home » Stocks » MyoKardia

MyoKardia, Inc. (MYOK)

Stock Price: $103.40 USD 3.13 (3.12%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $104.00 +0.60 (0.58%) Aug 7, 5:17 PM

Stock Price Chart

Key Info

Market Cap 5.45B
Revenue (ttm) 12.40M
Net Income (ttm) -334.02M
Shares Out 53.00M
EPS (ttm) -7.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $103.40
Previous Close $100.27
Change ($) 3.13
Change (%) 3.12%
Day's Open 100.01
Day's Range 99.61 - 104.22
Day's Volume 312,214
52-Week Range 42.65 - 126.30

More Stats

Market Cap 5.45B
Enterprise Value 4.58B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 53.00M
Float 51.55M
EPS (basic) -7.1
EPS (diluted) -7.07
FCF / Share -6.12
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.10M
Short Ratio 10.84
Short % of Float 33.28%
Beta 2.17
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 439.60
PB Ratio 5.83
Revenue 12.40M
Operating Income -342.89M
Net Income -334.02M
Free Cash Flow -304.99M
Net Cash 868.53M
Net Cash / Share 16.47
Gross Margin -1,823.96%
Operating Margin -2,765.27%
Profit Margin n/a
FCF Margin -2,459.63%
ROA -26.54%
ROE -44.75%
ROIC -112.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 11
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$137.45*
(32.93% upside)
Low
121
Current: $103.40
High
188
Target: 137.45
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-33.5611.4441.9714.205.92-
Revenue Growth-193.29%-72.74%195.59%140.01%--
Gross Profit-33.5611.4441.9714.205.92-
Operating Income-288-73.65-58.67-10.53-23.21-17.22-13.63
Net Income-276-67.70-57.01-10.38-22.95-16.83-12.70
Shares Outstanding44.7738.3932.8327.486.291.761.17
Earnings Per Share-6.17-1.76-1.74-0.38-4.48-11.30-11.98
Operating Cash Flow-242-64.82-9.84-20.86-32.1013.66-12.53
Capital Expenditures-3.26-3.37-1.51-1.08-1.31-0.72-1.17
Free Cash Flow-245-68.19-11.35-21.94-33.4112.94-13.70
Cash & Equivalents41831725714011243.651.91
Total Debt0.38------
Net Cash / Debt41831725714011243.651.91
Assets45640728320111746.894.70
Liabilities49.8236.6952.1355.9222.7132.212.56
Book Value40637123114593.87-36.91-17.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MyoKardia, Inc.
Country United States
Employees 235
CEO Anastasios E. Gianakakos

Stock Information

Ticker Symbol MYOK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MYOK
IPO Date October 29, 2015

Description

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company; and a strategic collaboration and license agreement with Fulcrum Therapeutics, Inc. to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.